Provided herein are antibodies that target tumors, wherein the binding of the antibody to the tumor is dependent on the expression of one or more glycosyltransferases in the tumor. These antibodies bind preferentially to tumor tissue as compared to normal tissue. Such antibodies are used in methods of inhibiting tumor cell growth.

Anti-EphA2 antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety and an anti-EphA2 antibody or antigen-binding fragment thereof that binds the antigen target, e.g., the antigen expressed on a tumor or other cancer cells. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making the same are also disclosed.

The present invention discloses a number of markers selectively deregulated in tumor-infiltrating regulatory T cells. The invention relates to molecules able to modulate the expression and/or function of at least one such marker for use in the prevention and/or treatment of the tumor. Preferably the molecule specifically binds to the marker and induces antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further relates to a molecule able to modulate the expression and/or function of at least one such marker for use in a method for in vivo depleting tumor-infiltrating regulatory T cell in a subject, or for use in a method to enhance tumor immunity in a subject. Corresponding pharmaceutical compositions are also contemplated.

The presently disclosed subject matter relates to a method for finding and identifying sites or regions on cancer cells that are not possessed by normal cells (neoantigens). The method comprises creation of xenoantibodies which are able to specifically bind to cancer cell specific sites, and do not bind to, or cross react with normal cells. These neoantigens are used to plan and create cancer treatments.

The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to L1-CAM (CD171), to a polynucleotide encoding at least one variable heavy chain sequence and/or at least one variable light chain sequence as in the antibody or an antigen binding fragment thereof of the present invention, to a host cell comprising the polynucleotide of the present invention, to an immunoconjugate comprising an antibody or an antigen-fragment binding thereof of the present invention and an active agent, to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof of the present invention, or the immunoconjugate of the present invention, and their use in treatment and/or diagnosis. The antibodies, antigen-binding fragments thereof, the immunoconjugates and the pharmaceutical compositions described herein are particularly useful in treatment or diagnosis of an L1-CAM (CD171) associated cancer.

Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.

A pharmaceutical composition comprising a compound that targets and/or binds to a binding pocket at interface between the D1 and D2 domains of an intracellular portion or fragment of the receptor protein tyrosine phosphatase (RPTP) IIb cell adhesion molecules (e.g., PTP) and that is capable of inhibiting RPTP mediated adhesion of cells and/or cancer cell growth and/or sphere formation.

Provided herein are various embodiments relating to anti-CCR8 binding agents, that bind to CCR8, and uses thereof. Some of the embodiments include antibodies, fragments thereof, variants thereof, derivatives thereof, and binding polypeptides targeting the same that bind CCR8. Such anti-CCR8 binding agents can be used in methods to treat, for example, cancer.

In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.

The present disclosure relates to genetically engineered phage that bind to cancer cells. The genetically engineered phage can be used to isolate cancer cells, for example, circulating cancer cells, by binding to antigens specifically expressed on the surface of cancer cells. Thus, the present disclosure provides compositions, methods, and kits for improved cancer diagnosis that are useful for improved cancer treatment.